List of Qtern drug patents

Qtern is owned by Astrazeneca Ab.

Qtern contains Dapagliflozin; Saxagliptin Hydrochloride.

Qtern has a total of 8 drug patents out of which 0 drug patents have expired.

Qtern was authorised for market use on 27 February, 2017.

Qtern is available in tablet;oral dosage forms.

Qtern can be used as treatment of type 2 diabetes mellitus; method for treating type 2 diabetes mellitus (t2dm) in patients who are already treated with dapagliflozin and saxagliptin; method for treating type 2 diabetes mellitus (t2dm) in patients who have inadequate control with dapagliflozin, treatment of type 2 diabetes mellitus, treatment of type 2 diabetes mellitus; method for treating type 2 diabetes mellitus (t2dm) in patients who have inadequate control with dapagliflozin; method for treating type 2 diabetes mellitus (t2dm) in patients who are already treated with dapagliflozin and saxagliptin.

The generics of Qtern are possible to be released after 16 December, 2029.

QTERN's oppositions filed in EPO
QTERN Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(4 months from now)

US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(2 years from now)

US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8628799 ASTRAZENECA AB Coated tablet formulation and method
Jul, 2025

(2 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(4 years from now)

US8221786 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(5 years from now)

US8716251 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(5 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Strength (NS) May 2, 2022
New Indication (I) May 2, 2022

Drugs and Companies using DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 February, 2017

Treatment: Treatment of type 2 diabetes mellitus; Method for treating type 2 diabetes mellitus (t2dm) in patients who have inadequate control with dapagliflozin; Method for treating type 2 diabetes mellitus (t2dm) in patients who are already treated with dapagliflozin and saxagliptin

Dosage: TABLET;ORAL

How can I launch a generic of QTERN before it's patent expiration?
More Information on Dosage

QTERN family patents

25

United States

14

Japan

13

China

11

Brazil

11

European Union

10

Korea, Republic of

9

Spain

9

Mexico

9

Taiwan, Province of China

8

Norway

8

Canada

7

Russia

7

New Zealand

7

Hong Kong

7

EA

7

Israel

6

Portugal

6

Argentina

6

Peru

6

Hungary

6

Slovenia

6

Poland

6

Denmark

5

Croatia

5

Australia

4

Malaysia

4

South Africa

4

Lithuania

4

ME

4

RS

3

Cyprus

3

Ukraine

2

Germany

2

Singapore

2

Colombia

2

Philippines

2

Austria

2

Belgium

2

India

2

Luxembourg

2

Georgia

2

Chile

1

Turkey

1

Uruguay

1

Egypt

1

Iceland

1

Yugoslavia

1

Czech Republic

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in